BridgeMD
ASPIRING
EU CTIS ID: 2024-516188-10-00
What this study is testing
ASPIRING will test the hypothesis that starting oral antiplatelet drug monotherapy is superior to avoiding antiplatelet drugs, in addition to standard care at the participating hospital, for increasing the time to first major adverse cardiovascular or cerebrovascular events (MACE) for survivors of stroke due to intracerebral haemorrhage (ICH).
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Stroke due to intracerebral haemorrhage (ICH), diagnosed by brain imaging, with symptom onset at least 24 hours before randomisation.
- Age ≥18 years at the time of first imaging diagnosis of ICH
- Radiological text report of the brain imaging study that first diagnosed the ICH is available
- Consent obtained from the participant (or their representative if the participant lacks mental capacity)
You likely can't join if
- ICH (intracerebral haemorrhage) exclusively caused by head injury.
- Pregnant, breast-feeding, or of child-bearing potential and not using highly effective contraception
- Previously enrolled in ASPIRING
- Enrolled in a study that precludes co-enrolment with ASPIRING
- ICH secondary to aneurysm, angiitis, arteriovenous malformation/fistula, cavernous malformation, coagulopathy, intracranial venous thrombosis, moyamoya disease, or tumour
- ICH due to hemorrhagic transformation of cerebral infarction
See the full eligibility criteria
- Stroke due to intracerebral haemorrhage (ICH), diagnosed by brain imaging, with symptom onset at least 24 hours before randomisation.
- Age ≥18 years at the time of first imaging diagnosis of ICH
- Radiological text report of the brain imaging study that first diagnosed the ICH is available
- Consent obtained from the participant (or their representative if the participant lacks mental capacity)
- ICH (intracerebral haemorrhage) exclusively caused by head injury.
- Pregnant, breast-feeding, or of child-bearing potential and not using highly effective contraception
- Previously enrolled in ASPIRING
- Enrolled in a study that precludes co-enrolment with ASPIRING
- ICH secondary to aneurysm, angiitis, arteriovenous malformation/fistula, cavernous malformation, coagulopathy, intracranial venous thrombosis, moyamoya disease, or tumour
- ICH due to hemorrhagic transformation of cerebral infarction
- Systolic blood pressure (BP) ≥160mmHg at randomisation
- Oral antiplatelet or oral anticoagulant drug, or aspirin over the counter, were taken within 24 hours before randomisation
- Investigator believes that prescription of a daily oral antiplatelet drug is required at the time of randomisation
- Antiplatelet drug use is contraindicated
- Death appears imminent
- Follow-up will not be possible for the primary and secondary outcomes
The study team makes the final eligibility decision.
Where it's taking place
- Canada
- Australia
- United Kingdom
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Canada; Australia; United Kingdom. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.